Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Receivables (2020 - 2025)

Cellebrite DI has reported Receivables over the past 6 years, most recently at $78.6 million for Q4 2025.

  • Quarterly results put Receivables at $78.6 million for Q4 2025, down 51.99% from a year ago — trailing twelve months through Dec 2025 was $78.6 million (down 51.99% YoY), and the annual figure for FY2025 was $78.6 million, down 51.99%.
  • Receivables for Q4 2025 was $78.6 million at Cellebrite DI, down from $163.7 million in the prior quarter.
  • Over the last five years, Receivables for CLBT hit a ceiling of $163.7 million in Q4 2024 and a floor of $78.6 million in Q4 2025.
  • Median Receivables over the past 5 years was $139.8 million (2021), compared with a mean of $126.4 million.
  • Biggest five-year swings in Receivables: surged 82.87% in 2024 and later plummeted 51.99% in 2025.
  • Cellebrite DI's Receivables stood at $139.8 million in 2021, then increased by 14.69% to $160.3 million in 2022, then tumbled by 44.15% to $89.5 million in 2023, then soared by 82.87% to $163.7 million in 2024, then plummeted by 51.99% to $78.6 million in 2025.
  • The last three reported values for Receivables were $78.6 million (Q4 2025), $163.7 million (Q4 2024), and $89.5 million (Q4 2023) per Business Quant data.